Anna Gisselsson

Director/Board Member at Moroxite F AB

Finance

Consumer Services

Commercial Services

Profile

Anna Gisselsson is currently working as a Director at Moroxite F AB and as an Investment Manager at Almi Invest AB.
She has a graduate and doctorate degree from the Faculty of Engineering, Lund University.

Anna Gisselsson active positions

Companies	Position	Start
Almi Invest AB Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden.	Private Equity Investor	01/11/2020
Moroxite F AB Moroxite F AB Miscellaneous Commercial ServicesCommercial Services Moroxite F AB has developed a regenerative medicine approach for fragility fractures, which improves implant anchorage and reduces fixation failures, re-operations, societal costs, and improves quality of life. The company is based in Lund, Sweden. The Swedish company has also developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures.	Director/Board Member	-

All active positions of Anna Gisselsson

Training of Anna Gisselsson

Faculty of Engineering, Lund University

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Anna Gisselsson's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Almi Invest AB Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden.	Finance
Moroxite F AB Moroxite F AB Miscellaneous Commercial ServicesCommercial Services Moroxite F AB has developed a regenerative medicine approach for fragility fractures, which improves implant anchorage and reduces fixation failures, re-operations, societal costs, and improves quality of life. The company is based in Lund, Sweden. The Swedish company has also developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures.	Commercial Services